MAP2K1 and infection: To examine the effects of MEK1/2 inhibitor treatments on bacterial burdens, quantification of CFU from lung homogenates at 4 hours post-infection revealed that the ATR-002-treated group had a significant reduction in bacterial burdens compared to vehicle or PD0325901-treated groups (Fig. 4A).